The company utilizes monoclonal antibodies to deliver radioisotopes directly to specific cells, effectively killing them. Their lead products include Iomab-B, used for hematopoietic stem cell transplantation, and Actimab-A, currently in clinical trials for acute myeloid leukemia. Actinium Pharmaceuticals focuses on myeloablation, hematopoietic stem cell and bone marrow transplants, and acute myeloid leukemia.